‘Dark matter’ creates a whole new level of cancer gene activity in tumors, researchers say
A whole new level of control of cancer gene activity within tumors, has been described…
A whole new level of control of cancer gene activity within tumors, has been described…
Update (25/06/2018): Oryzon enrolls first patients in the UK in its clinical trial testing its epigenetic…
CellCentric has raised a private round to fund the development of a first-in-class drug with…
Multiple sclerosis is the most common disease of the CNS in young adults. Researchers may…
4SC's partner Yakult Honsha has presented positive results at ESMO 2017 for the epigenetics drug…
The field of genetics has long been an object of global fascination, beginning with Mendel’s…
Scientists from the University of Zurich have identified an epigenetic control switch responsible for turning…
Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging…
Located right here in Barcelona, Oryzon is one of the world's few epigenetics biotechs. I…
After an amazing day in Paris for Labiotech Refresh, we head back to Germany to…
Giants like BMS and GSK have been throwing all the money they can at developing…
Not all tumours are detectable, which makes them particularly deadly. Researchers at the University of…